FDA Offers Guidance on Risk-Based Trial Monitoring for Phase II, IV
Source: PharmaManufacturing.com
Aug 12, 2013
in-Pharma Technologist.com
The US FDA has finalized guidance on clinical trial oversight, calling for more remote and targeted risk-based monitoring, though some experts believe such monitoring should be more judiciously employed. Read the full story
Show Comments
Join the discussion
We welcome your thoughtful comments.
All comments will display your user name.
Comments
No one has commented on this page yet.
RSS feed for comments on this page | RSS feed for all comments